Prescriber's Corner

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma

Krista G. Ramirez, PharmD, BCPS

Greenville Health System, Greer, South Carolina

Krista G. Ramirez, PharmD, BCPS, 845-D South Buncombe Road, Greer, South Carolina 29650. E-mail: KRamirez@ghs.org


J Adv Pract Oncol 2017;8:401–405 | https://doi.org/10.6004/jadpro.2017.8.4.9 | © 2017 Harborside Press®


  

ABSTRACT

The FDA approval of ixazomib for use in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy signalled the arrival of the first oral proteasome inhibitor, allowing advanced practitioners to provide multiple myeloma patients an exclusively oral triplet therapy.



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here